Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.

Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.

Methods: Patients received BLV 2 mg ± pegylated interferon-α (pegIFNα) according to the physician's decision.

Incidence of endoleak type IA in patients undergoing chimney endovascular aortic repair (ChEVAR) vs. standard endovascular repair.

Objectives: Almost half of endovascular aortic aneurysm repair (EVAR) procedures are performed in hostile anatomy, increasing the risk of procedure related complications such as type IA endoleaks, which may be prevented with the chimney technique in EVAR (ChEVAR). Our aim is to describe the differential characteristics between EVAR in favorable anatomy and ChEVAR in hostile necks.

Materials And Methods: A cohort of patients with infrarenal abdominal aortic aneurysms (AAA) that were treated with EVAR or ChEVAR were included.

Prognostic relevance of female gender on mortality after peripheral artery disease revascularization.

Introduction: Lower limb peripheral artery disease (PAD) presents high morbidity and mortality. Women represent a small subgroup in different studies, with scarce evidence regarding the prognosis of this gender on PAD. The aim of the present work was to determine the prognostic impact of female gender on lower limb PAD revascularization.

[Procedural and long-term outcomes of elective endovascular abdominal aortic aneurysm repair in octogenarians].

Objective: The aim of the study was to compare the immediate and long-term outcomes of endovascular aneurysm repair (EVAR) between patients under and over the age of 80 with abdominal aortic aneurysm (AAA).

Methods: From 2011 to 2017, we conducted a retrospective cohort study with AAA patients who received elective EVAR. Primary outcomes included hospital mortality, length of stay, acute kidney injury, and the need for re-interventions.

[Extracorporeal membrane oxygenation in COVID-19].

Introduction: The role of the use of Extracorporeal Membrane Oxygenation (ECMO) in patients with coronavirus disease (COVID-19) is under discussion. Whereas in patients with Acute Respiratory Distress Syndrome (ARDS) the ECMO is a usual rescue measure used to optimize the oxygenation as a bridge to pulmonary rehabilitation, in patients that have refractory hypoxemic respiratory failure with recovery potential, the use of ECMO could also be beneficial.

Objective: The purpose of this work is to report the first case of COVID-19 that required ECMO in Argentina, with a good response.